Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
1983
DOI: 10.1097/00132586-198304000-00020
|View full text |Cite
|
Sign up to set email alerts
|

Analgesic Responses to I.V. Lignocaine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
45
1
2

Year Published

2001
2001
2017
2017

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 40 publications
(50 citation statements)
references
References 0 publications
2
45
1
2
Order By: Relevance
“…topically. Administration systemically has, on the other hand, been found inadequate for blocking peripheral nociceptive pathways in higher vertebrates (mice, rat, cat and man; Boas et al 1982;Haegerstam 1979;Rigon and Takahashi 1996;Wiesenfeld-Hallin and Lindblom 1985;Woolf and Wiesenfeld-Hallin 1985). Haegerstam (1979) concluded that it was unlikely that peripheral pain pathways could be blocked by systemic i.v.…”
Section: Nociception In Fishmentioning
confidence: 99%
“…topically. Administration systemically has, on the other hand, been found inadequate for blocking peripheral nociceptive pathways in higher vertebrates (mice, rat, cat and man; Boas et al 1982;Haegerstam 1979;Rigon and Takahashi 1996;Wiesenfeld-Hallin and Lindblom 1985;Woolf and Wiesenfeld-Hallin 1985). Haegerstam (1979) concluded that it was unlikely that peripheral pain pathways could be blocked by systemic i.v.…”
Section: Nociception In Fishmentioning
confidence: 99%
“…The response was compared with that of ischemic pain. Disorders manifesting as deafferentation or central neuralgias appeared in that study to be affected favorably by lidocaine IV whereas pain of peripheral origin remained unaffected [74]. The lack of an oral agent and the need for ECG monitoring during the infusion along with its associated adverse effects render intravenous lidocaine an unpopular treatment choice.…”
Section: Lidocaine and Mexiletinementioning
confidence: 84%
“…Intravenous lidocaine has been shown to be beneficial in the relief of neuropathic pain in a few studies [73,74]. In a randomized, double-blind, cross-over study of patients with painful diabetic neuropathy of more than 6 months duration, intravenous lidocaine was shown to have a significant beneficial effect 1 and 8 days after infusion compared with after saline infusion (P Ͻ 0.05 and P Ͻ 0.02, respectively) [73].…”
Section: Lidocaine and Mexiletinementioning
confidence: 99%
See 1 more Smart Citation
“…The IC 50 for lidocaine's inhibition of sodium current in an unstimulated peripheral nerve is ≥200 μM (Hille 1977;Chernoff and Strichartz 1990;Docherty and Farrag 2006). However, when administered systemically, lidocaine is reported to produce substantial relief of neuropathic pain in humans (Boas et al 1982;Brose and Cousins 1991;Rowbotham et al 1991;Galer et al 1996) and profound reversal of tactile allodynia in rats (Abram and Yaksh 1994;Chaplan et al 1995;Sinnott et al 1999) at plasma concentrations ≤2 μg/ml (≤8.5 μM), i.e., over 24-fold less than the in vitro IC 50 .…”
Section: Discussionmentioning
confidence: 98%